A new model for secondary prevention of stroke: transition coaching for stroke

Cheryl Bushnell, Martinson Arnan, Sangwon Han, Cheryl Bushnell, Martinson Arnan, Sangwon Han

Abstract

Non-adherence to stroke prevention medications is a risk factor for first-ever and recurrent stroke. As of yet, there are no guidelines for processes to recognize and address medication non-adherence in stroke patients. We developed a new model of post-discharge prevention care that measures and addresses medication-taking (transition coaching for stroke or TRACS). TRACS includes personalized education about risk factors and medications prior to discharge, follow-up telephone calls, and appointments with a stroke nurse practitioner (NP). The stroke NP asks about medication use (persistence) and whether doses are missed (adherence), and helps to solve problems with access to medications or side effects. In an analysis of 142 patients enrolled in TRACS from October 2012 to February 2014, medication persistence (use of medications from discharge to the time of measurement) was about 80%. Medication persistence at NP visit was higher in those patients with a first-ever stroke (78.9%) vs. those with recurrent stroke (60.7%; p = 0.045). Concerted efforts with 2-day RN follow-up calls and earlier NP appointments to improve medication-taking behaviors are underway.

Keywords: medication adherence; quality improvement; stroke secondary prevention.

References

    1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics – 2014 update a report from the American Heart Association. Circulation (2014) 129:e28–292.10.1161/01.cir.0000441139.02102.80
    1. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 45(7):2160–236.10.1161/STR.0000000000000024
    1. Heidenreich P. Patient adherence: the next frontier in quality improvement. Am J Med (2004) 117:130–2.10.1016/j.amjmed.2004.03.007
    1. Lager KE, Mistri AK, Khunti K, Haunton VJ, Sett AK, Wilson AD. Interventions for improving modifiable risk factor control in the secondary prevention of stroke. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; (2014). Available from:
    1. Gehi AK, Ali S, Na B, Whooley MA. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch Intern Med (2007) 167:1798–803.10.1001/archinte.167.16.1798
    1. Ovbiagele B, Campbell S, Faiz A, Chambless L. Relationship between non-specific prescription pill adherence and ischemic stroke outcomes. Cerebrovasc Dis (2010) 29:146–53.10.1159/000262311
    1. Bailey J, Wan J, Tang J, Ghani M, Cushman W. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med (2010) 25:495–503.10.1007/s11606-009-1240-1
    1. Shaya F, El Khoury A, Mullins C, Du D, Skolasky R, Fatodu H, et al. Drug therapy persistence and stroke recurrence. Am J Manag Care (2006) 12:313–9.
    1. Rodriguez F, Cannon CP, Steg PG, Kumbhani DJ, Goto S, Smith SC, et al. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the reach registry. Clin Cardiol (2013) 36:721–7.10.1002/clc.22217
    1. Bushnell C, Zimmer L, Schwamm L, Goldstein L, Clapp-Channing N, Harding T, et al. The adherence evaluation after ischemic stroke longitudinal (AVAIL) registry: design, rationale, and baseline patient characteristics. Am Heart J (2009) 157:428–35.10.1016/j.ahj.2008.11.002
    1. Bushnell CD, Zimmer LO, Pan W, Olson DM, Zhao X, Meteleva T, et al. Persistence with stroke prevention medications 3 months after hospitalization. Arch Neurol (2010) 67:1456–63.10.1001/archneurol.2010.190
    1. Bushnell C, Olson D, Zhao X, Pan W, Zimmer L, Goldstein L, et al. Secondary preventive medication persistence and adherence one-year after stroke. Neurology (2011) 77:1182–90.10.1212/WNL.0b013e31822f0423
    1. Lummis H, Sketris I, Gubitz G, Joffres M, Flowerdew G. Medication persistence rates and factors associated with persistence in patients following stroke: a cohort study. BMC Neurol (2008) 8:25.10.1186/1471-2377-8-25
    1. Glader E-V, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke (2010) 41:2552–8.10.1161/STROKEAHA.109.566950
    1. Ovbiagele B, Saver JL, Fredieu A, Suzuki S, Selco S, Rajajee V, et al. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke (2004) 35:2879–83.10.1161/01.STR.0000147967.49567.d6
    1. Ovbiagele B, Kidwell C, Selco S, Razinia T, Saver J. Treatment adherence rates one year after initiation of a systematic hospital-based stroke prevention program. Cerebrovasc Dis (2005) 20:280–2.10.1159/000087711
    1. Sides E, Zimmer L, Wilson L, Pan W, Olson D, Peterson ED, et al. Medication coaching program for patients with minor stroke or TIA: a pilot study. BMC Public Health (2012) 12:549.10.1186/1471-2458-12-549
    1. Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. Scott Med J (1957) 2:200–15
    1. Duncan PW, Wallace D, Lai SM, Johnson D, Embretson S, Laster LJ. The Stroke Impact Scale version 2.0 evaluation of reliability, validity, and sensitivity to change. Stroke (1999) 30:2131–40.10.1161/01.STR.30.10.2131
    1. Duncan P, Lai S, Bode R, Perera S, DeRosa J. Stroke Impact Scale-16: a brief assessment of physical function. Neurology (2003) 60:291–6.10.1212/01.WNL.0000041493.65665.D6
    1. The EuroQol Group. EuroQol* – a new facility for the measurement of health-related quality of life. Health Policy (1990) 16:199–208.10.1016/0168-8510(90)90421-9
    1. Strowd RE, Wise SM, Umesi UN, Bishop L, Craig J, Lefkowitz D, et al. Predictors of 30-day hospital readmission following ischemic and hemorrhagic stroke. Am J Med Qual (2014).10.1177/1062860614535838
    1. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; (2001).
    1. Sjolander M, Eriksson M, Glader E-L. The association between patients’ beliefs about medicines and adherence to drug treatment after stroke: a cross-sectional questionnaire survey. BMJ Open (2013) 3(9):e003551.10.1136/bmjopen-2013-003551
    1. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med (2005) 61:133–55.10.1016/j.socscimed.2004.11.063
    1. Souter C, Kinnear A, Kinnear M, Mead G. Optimisation of secondary prevention of stroke: a qualitative study of stroke patients’ beliefs, concerns and difficulties with their medicines. Int J Pharm Pract (2014).10.1111/ijpp.12104

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi